Adding liraglutide to continuous subcutaneous insulin infusion significantly reduces glycated hemoglobin without increasing hypoglycemia in overweight and obese people with type 1 diabetes and suboptimal glycemic control, Danish research shows.
Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.
Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.
Findings from a dose-ranging phase II trial published in The Lancet suggest that semaglutide, in combination with lifestyle intervention, may aid weight loss in people with obesity who do not have diabetes.
The National Institute For Health and Care Excellence has issued an evidence summary to support use of the glucagon-like peptide-1 receptor agonist liraglutide in obese and overweight individuals with risk factors, such as dysglycemia.